SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer (SMCI) is trending following a Goldman Sachs downgrade to a "Sell" rating and a $26 price target, which the community widely perceives as an attempt to manipulate shares. Despite concerns over profitability and competition raised by the downgrade, many highlight SMCI's critical role in the expanding AI infrastructure market, anticipating strong revenue growth in upcoming earnings to affirm its undervalued position.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is a major talking point following its strong quarterly earnings, which showcased robust trading revenue and record performance in its wealth management division, exceeding market expectations. The community is buzzing about the strategic acquisition of the Apple Card portfolio and CEO Jamie Dimon's cautiously optimistic economic commentary, with ongoing speculation about a potential stock split and new ventures into crypto.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is a major talking point following an analyst upgrade to Overweight, which cites strong momentum in the company's AI accelerators and upcoming chip pipeline. The community is actively discussing AMD's potential to drive significant growth in the AI sector, although recent price movements are fueling a lively debate between those anticipating further gains and others concerned about short-term volatility.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is trending after reporting strong earnings that surpassed profit expectations and providing an optimistic full-year outlook, driven by robust premium travel demand and loyalty program growth. This positive performance, coupled with the CEO's remarks downplaying the impact of the government shutdown on demand, has ignited significant community discussion and is boosting confidence across the airline sector.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

BriaCell Therapeutics Corp - Ordinary Shares - New

BriaCell Therapeutics Corp

BriaCell Therapeutics is trending following news of an upcoming 1-for-10 reverse stock split, stirring significant community concern over its history of repeated dilutions and share price depreciation. Despite recent positive announcements, including a $2 million NCI grant and peer-reviewed publication on its cancer immunotherapies, widespread skepticism persists regarding management's financing strategies. This situation underscores the ongoing tension in clinical-stage biotech between funding scientific advancement and maintaining investor confidence.

Ambitions Enterprise Management Co. LLC operates as a travel agency. It provides event planning and management services. The firm also offers transportation, accommodations, meals, and guided tours or activities under convenient packages. The company was founded on October 26, 2023 and is headquartered in Dubai, United Arab Emirates.

Ambitions Enterprise Management Co LLC - Ordinary Shares - Class A

Ambitions Enterprise Management Co LLC

AHMA is experiencing explosive price action and massive trading volume, with many in the community noting a lack of specific news driving the surge. Discussions revolve around its extremely low float and recent IPO status, leading to speculation about a potential short squeeze reminiscent of other highly volatile low-float runners. Traders are actively debating scalping opportunities versus holding for substantial gains, alongside cautious warnings of potential manipulation.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI Corp. is gaining significant attention, notably ahead of its presentation at the Needham Growth Conference, propelled by recent advancements like securing a key U.S. patent for coordinated autonomous sensor networks and forming Palladyne Defense. The community is highly bullish, anticipating major government contracts for its AI and robotics technology, viewing it as a significantly undervalued play poised to benefit from increasing defense spending and national security initiatives. Many expect a substantial upside, driven by these catalysts and potential short squeeze dynamics.

L3Harris Technologies, Inc. engages in the provision of defense and commercial technologies across the air, land, sea, space, and cyber domains. It operates through the following segments: Space and Airborne Systems, Integrated Mission Systems, Communication Systems, and Aerojet Rocketdyne. The Space and Airborne Systems segment provides full mission solutions as a prime and subsystem integrator in the space, airborne and cyber domains. The Integrated Mission Systems segment focuses on the differentiated mission capabilities and prime systems integration for the air, land and sea domains. The Communication Systems segment enables warfighters across all domains with solutions critical to mission success even in the most contested environments. The Aerojet Rocketdyne segment includes propulsion, power and armament products and systems to U.S. government, including the DoD, National Aeronautics and Space Administration (“NASA”) and major aerospace and defense prime contractors. The company was founded in 1890 and is headquartered in Melbourne, FL.

L3Harris Technologies Inc

L3Harris is trending due to its plan to spin off its Missile Solutions unit into a standalone company, supported by significant government investment aimed at boosting U.S. rocket motor production capacity. The community is enthusiastic about the potential to unlock hidden value and strategically position the new entity within the robust defense sector, aligning with broader national security priorities and increasing demand for advanced missile systems.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is currently trending with immense bullish sentiment, as the 'Spacemob' community eagerly anticipates updates on key satellite deployments and future launch schedules, alongside the deepening of strategic partnerships with major global telecom and space entities. Discussions highlight ASTS's patented direct-to-device technology as a disruptive force, positioning it uniquely within the rapidly evolving space and defense communication sector, and sparking fierce debate between long-term holders eyeing significant future growth and persistent short interest.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), Global Services (BGS), and Boeing Capital (BCC). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The Boeing Capital segment seeks to ensure that Boeing customers have the financing they need to buy and take delivery of their Boeing product and manages overall financing exposure. The company was founded by William Edward Boeing on July 15, 1916 and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending amidst strong bullish sentiment, fueled by a wave of significant new aircraft orders from key airlines like Delta and Alaska, coupled with substantial defense contracts. The community is actively discussing signs of an operational turnaround, with improving production rates and a massive backlog positioning the company for significant upside as it addresses past challenges and capitalizes on robust market demand.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Mereo BioPharma Group (NASDAQ:MREO) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen lowered Mereo BioPharma Group from a "hold" rating to a "sell" rating in a report on Saturday...

Mereo BioPharma Group Sees Unusually Large Options Volume (NASDAQ:MREO)

Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO - Get Free Report) was the target of some unusual options trading activity on Wednesday. Stock investors acquired 4,381 call options on the...

RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint

Ultragenyx and Mereo BioPharma shares fall as phase III Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta miss primary endpoints.

Nasdaq Falls Over 100 Points Amid Decline In Tech Stocks: Investor Sentiment Weakens, Fear & Greed Index In 'Neutral' Zone

U.S. stocks fell on Monday, with Nasdaq down 100 points. Nvidia Corp. and Mereo BioPharma Group plc also experienced declines.read more...

<ul class="summary-bullets"><li>The company said that results from the Phase 3 Orbit and Cosmic studies for an experimental drug designed to help people with brittle bone disease did not significantly reduce annualized clinical fracture rates.</li><li>Both studies showed improvements in bone mineral density, the company said.&nbsp;</li><li>Ultragenyx also noted that it will reduce expenses significantly after evaluating its planned operations.</li></ul>Ultragenyx Pharmaceutical Inc. (RARE) shares plunged over 41% on Monday after the company announced disappointing results from its Phase 3 studies for its experimental drug designed to help people with brittle bone disease.The company said that results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI), conducted in partnership with Mereo Biopharma (MREO), did not significantly reduce annualized clinical fracture rates compared to placebo or bisphosphonates, respectively. However, both studies showed improvements in bone mineral density, the company said.The firm also said it will significantly reduce expenses after evaluating its planned operations.<h2 class="st-heading-2">Trial Details</h2>In the Orbit study, participants showed substantial improvements in bone mineral density compared with the placebo group. However, that did not result in a significant reduction in annualized fracture rates, since the placebo group also had a low fracture rate, the company noted.In the Cosmic study, which included pediatric patients, the baseline fracture rate was substantially higher than in the Orbit patient group. While the study showed improvements in bone mineral density and a reduction in annualized fracture rate compared to bisphosphonate-treated patients, the results were not statistically significant.“We are surprised and disappointed by these results given the promising data from our Phase 2 study and the lack of approved treatment options available to patients with OI who live with significant pain, disability, and disease burden,” said Emil Kakkis, chief executive officer and president of Ultragenyx. “We continue to explore the data to gain deeper understanding of the findings.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RARE">RARE shares</a> jumped to ‘extremely bullish’ from ‘bearish’ territory over the past day, while message levels jumped to ‘extremely high’ levels at the time of writing. The stock was also among the top trending tickets on the platform.<figure class="image"><img style="aspect-ratio:1283/153;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_29_at_9_02_19_PM_png_233d427277.webp" alt="On Stocktwits, retail sentiment around RARE shares jumped to ‘extremely bullish’ from ‘bearish’ territory over the past day, while message levels jumped to ‘extremely high’ levels at the time of writing. " width="1283" height="153"></figure>Shares of RARE are down over 51% in the past year.Editor's Note: The story has been updated to reflect that the Phase 3 Orbit and Cosmic studies for setrusumab in Osteogenesis Imperfecta was conducted in partnership with Mereo Biopharma.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the Ultragenyx Pharmaceutical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did RARE Stock Plunge Over 41% Today?

Ultragenyx Pharmaceutical announced disappointing results from its Phase 3 studies for the setrusumab (UX143) in the Osteogenesis Imperfecta (OI) program. 

Equity

Ultragenyx-Mereo Bone Drug Trial Disappoints, Stocks Hit 52-Week Lows

Ultragenyx and Mereo BioPharma hit 52-week low after disappointing results from Phase 3 studies for Osteogenesis Imperfecta treatment.read more...

Mereo BioPharma, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Mereo BioPharma Group (NASDAQ:MREO) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC restated a "buy" rating and set a $5.00 price objective on shares of Mereo BioPharma Group in a research note on Monday...

Mereo BioPharma Group plc - Sponsored ADR $MREO Shares Bought by Frazier Life Sciences Management L.P.

Frazier Life Sciences Management L.P. lifted its stake in shares of Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO - Free Report) by 20.7% during the second quarter, according to its most...

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Mereo Biopharma Group Plc - ADR

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$0.5673
Prev Close	$0.4944
Open	$0.566
Dividend Yield	0.00%
50-Day Moving Average	$1.65
Beta	1.68
Avg. Volume	18.97M
PE Ratio	-2.15

52-Week High	$3.39
52-Week Low	$0.20
Market Capitalization	$90.26M
EPS (Annual)	-$0.2925
Price to Book	1.94
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

MREO
Mereo Biopharma

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MREO News

MREOMereo Biopharma